Thanks,
I'll have to re-read, to get the whole picture. When I went through it originally there was this snippet "Management have told the market that the full year result is expected to be strong even
with some seasonality. A conservative assumption would be a 55/45 earnings split for 1H/2H
given some seasonality in ITL Healthcare, but ITL BioMedical may post a more impressive
performance (say 50/50 split or a bit better). That would have the stock trading on 11-12x
earnings for FY17 based on current prices.
But couldn't identify the reasoning, it is a big document so I probably skimmed over most of it.
I agree that this stock is significantly undervalued.
- Forums
- ASX - By Stock
- ITD
- Ann: National Diabetes Week drives demand for MyHealthTest
Ann: National Diabetes Week drives demand for MyHealthTest, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ITD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online